Dealing with Misinformation

Therapeutic Agents in Clinical Trials

Dr Wainberg and Dr Gerson identify some of the challenges of preclinical models versus clinical trials.

How MSI and TMB Factor into Current Biomarker Testing Panels

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”